Drug metabolism and clearance system in tumor cells of patients with multiple myeloma

Oncotarget

Volumn 6, Issue 8, 2015, Pages 6431-6447

  Hassen, Wafa ^a,b   Kassambara, Alboukadel ^a,c   Reme, Thierry ^a,c   Sahota, Surinder ^d   Seckinger, Anja ^e,f   Vincent, Laure ^c   Cartron, Guillaume ^c   Moreaux, Jérôme ^a,c,g   Hose, Dirk ^e,f   Klein, Bernard ^a,c,g  

^a CNRS   (France)

^b UNIVERSITY OF MONASTIR   (Tunisia)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f Nationales Centrum fur Tumorerkrankungen   (Germany)

^g UNIV MONTPELLIER   (France)

Author keywords

Drug metabolism and clearance; Multiple myeloma; Prognosis

Indexed keywords

ABC TRANSPORTER; CONSTITUTIVE ANDROSTANE RECEPTOR; DRUG METABOLIZING ENZYME; FARNESOID X RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1BETA; LIVER X RECEPTOR; RETINOID X RECEPTOR ALPHA; TRANSCRIPTION FACTOR NRF2; ANTINEOPLASTIC AGENT; CARRIER PROTEIN;

ARNT GENE; ARTICLE; CANCER PROGNOSIS; CONSTITUTIVE ANDROSTANE RECEPTOR GENE; DOWN REGULATION; EVENT FREE SURVIVAL; FARNESOL X RECEPTOR GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER X RECEPTOR GENE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NUCLEAR FACTOR ERYTHROID 2P45 RELATED FACTOR 2 GENE; OVERALL SURVIVAL; RXR ALPHA GENE; METABOLISM; MULTIDRUG RESISTANCE; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DRUG RESISTANCE, MULTIPLE; HUMANS; MULTIPLE MYELOMA; PROGNOSIS;

EID: 84925649577     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3237     Document Type: Article

References (69)

1. Morgan GJ, Walker BA, Davies FE. The genetic architecture ofmultiple myeloma. Nature Publishing Group. Nature Publishing Group; 2012;12:335-48.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. The Lancet. Elsevier Ltd; 2009;374:324-39.
3. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood. 2011;118:3205-11.
4. Chen Y, Tang Y, Guo C, Wang J, Boral D, Nie D. Biochemical Pharmacology. Biochem. Pharmacol. Elsevier Inc; 2012;83:1112-26.
5. Akhdar H, Legendre C, Aninat C and More F. Anticancer Drug Metabolism: Chemotherapy Resistance and New Therapeutic Approaches, Topics on Drug Metabolism, Dr. James Paxton (Ed.), ISBN: 2012, 978-953-51-0099-7, InTech, Available from: http://www.intechopen.com/books/topics-on-drug-metabolism/anticancer-drug-metabolism-chemotherapy-resistance-and-new-therapeutic-approaches .
6. Ma Q. Xenobiotic-Activated Receptors: From Transcription to Drug Metabolism to Disease. Chem. Res. Toxicol. 2008;21:1651-71.
7. Döring B, Petzinger E. Phase 0 and phase III transport in various organs: Combined concept of phases in xenobiotic transport and metabolism. Drug Metabolism Reviews. 2014;:1-22.
8. Omiecinski CJ, Vanden Heuvel JP, Perdew GH, Peters JM. Xenobiotic Metabolism, Disposition, and Regulation by Receptors: From Biochemical Phenomenon to Predictors of Major Toxicities. Toxicological Sciences. 2011;120:S49-S75.
9. Conney AH. I NDUCTION OFD RUG-M ETABOLIZINGE NZYMES: A Path to the Discovery of Multiple Cytochromes P450*. Annu. Rev. Pharmacol. Toxicol. 2003;43:1-30.
10. Zanger UM, Schwab M. Pharmacology & Therapeutics. Pharmacology and Therapeutics. Elsevier Inc; 2013;138:103-41.
11. Gamage N. Human Sulfotransferases and Their Role in Chemical Metabolism. Toxicological Sciences. 2005;90:5-22.
12. Wells PG, Mackenzie PI, Chowdhury JR, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Chowdhury NR, Ritter JK. Drug Metab Dispos. 2004 Mar;32(3):281-90. 2004;:1-10.
13. Scotto KW. Transcriptional regulation of ABC drug transporters. Oncogene. 2003;22:7496-511.
14. Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, Giacomini KM, Hillgren KM. Highlights from the International Transporter Consortium Second Workshop. Clin Pharmacol Ther. 2012;92:553-6.
15. Yu M, Ocana A, Tannock IF. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev. 2012;32:211-27.
16. Pondugula SR, Mani S. Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Letters. 2013;328:1-9.
17. Walsh JS, Miwa GT. Bioactivation of Drugs: Risk and Drug Design. Annu. Rev. Pharmacol. Toxicol. 2011;51:145-67.
18. Tang J. Expression of the PXR gene in various types of cancer and drug resistance (Review). Oncol Lett. 2013.
19. Gold LS, De Roos AJ, Brown EE, Lan Q, Milliken K, Davis S, et al. Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiology. 2009;33:276-80.
20. Tanaka T, De Luca LM. Therapeutic Potential of "Rexinoids" in Cancer Prevention and Treatment. Cancer Research. 2009;69:4945-7.
21. Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br. J. Dermatol. 2007;157:433-40.
22. Evans RM, Mangelsdorf DJ. Nuclear Receptors, RXR, and the Big Bang. Cell. 2014;157:255-66.
23. Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F, et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res. 2012;40:7416-29.
24. Ouyang N, Ke S, Eagleton N, Xie Y, Chen G, Laffins B, et al. Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. British Journal of Cancer. Nature Publishing Group; 2010;102:1753-61.
25. Verma S, Tabb MM, Blumberg B. Activation of the steroid and xenobiotic receptor, SXR, induces apoptosis in breast cancer cells. BMC Cancer. 2009;9:3.
26. Zhuo W, Hu L, Lv J, Wang H, Zhou H, Fan L. Role of pregnane X receptor in chemotherapeutic treatment. Cancer Chemother Pharmacol. 2014.
27. Robbins D, Chen T. Tissue-specific regulation of pregnane X receptor in cancer development and therapy. Cell & Bioscience. Cell & Bioscience; 2014;4:1-8.
28. Agarwal JR, Wang Q, Tanno T, Rasheed Z, Merchant A, Ghosh N, et al. Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma. Molecular Cancer Therapeutics. 2014;13:1873-81.
29. Petzinger E, Geyer J. Drug transporters in pharmacokinetics. Naunyn Schmiedebergs Arch. Pharmacol. 2006;372:465-75.
30. Lin J, Raoof DA, Thomas DG, Greenson JK, Giordano TJ, Robinson GS, et al. L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia. 2004;6:74-84.
31. Kühne A, Kaiser R, Schirmer M, Heider U, Muhlke S, Niere W, et al. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Pharmacogenet Genomics. 2007;17:505-17.
32. Kühne A, Tzvetkov MV, Hagos Y, Lage H, Burckhardt G, Brockmöller J. Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem. Pharmacol. 2009;78:45-53.
33. Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, et al. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin. Cancer Res. 2011;17:7402-12.
34. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 2000;59:961-72.
35. Wang D, Li L, Yang H, Ferguson SS, Baer MR, Gartenhaus RB, et al. The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies. Blood. 2013;121:329-38.
36. Tsubaki M, Satou T, Itoh T, Imano M, Komai M, Nishinobo M, et al. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. Leukemia Research. 2012;36:1315-22.
37. Tsubaki M, Komai M, Itoh T, Imano M, Sakamoto K, Shimaoka H, et al. By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. Leukemia Research. 2014;38:121-30.
38. Martino A, Sainz J, Reis RM, Moreno V, Buda G, Lesueur F, et al. Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. Journal of Human Genetics. Nature Publishing Group; 2013;58:155-9.
39. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, Larson RA, et al. Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer. 2006;106:830-8.
40. Januchowski R, Zawierucha P, Andrzejewska M, Rucinski M, Zabel M. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomed. Pharmacother. 2013;67:240-5.
41. Szakács G, Annereau J-P, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004;6:129-37.
42. Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1a overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia. 2010;24:1967-70.
43. Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, et al. Hypoxia-inducible factor (HIF)-1a suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia. 2013;27:1697-706.
44. Hu Y, Kirito K, Yoshida K, Mitsumori T, Nakajima K, Nozaki Y, et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Molecular Cancer Therapeutics. 2009;8:2329-38.
45. Sherr DH, Monti S. The role of the aryl hydrocarbon receptor in normal and malignant B cell development. Semin Immunopathol. 2013;35:705-16.
46. Feng S, Cao Z, Wang X. Biochimica et Biophysica Acta. BBA-Reviews on Cancer. Elsevier B.V; 2013;1836:197-210.
47. Casado FL, Singh KP, Gasiewicz TA. Blood Cells, Molecules, and Diseases. Blood Cells, Molecules, and Diseases. Elsevier Inc; 2010;44:199-206.
48. Safe S, Lee SO, Jin UH. Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target. Toxicological Sciences. 2013;135:1-16.
49. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603-7.
50. Haarmann-Stemmann T, Abel J, Fritsche E, Krutmann J. The AhR-Nrf2 pathway in keratinocytes: on the road to chemoprevention? J. Invest. Dermatol. 2012;132:7-9.
51. Shin S, Wakabayashi N, Misra V, Biswal S, Lee GH, Agoston ES, et al. NRF2 modulates aryl hydrocarbon receptor signaling: influence on adipogenesis. Mol. Cell. Biol. 2007;27:7188-97.
52. Gu C, Gonzalez J, Zhang T, Kamel-Reid S, Wells RA. Leukemia Research. Leukemia Research. Elsevier Ltd; 2013;37:1750-6.
53. Shieh J-M, Shen C-J, Chang W-C, Cheng H-C, Chan Y-Y, Huang W-C, et al. An Increase in Reactive Oxygen Species by Deregulation of ARNT Enhances Chemotherapeutic Drug-Induced Cancer Cell Death. Chang Y-J, editor. PLoS ONE. 2014;9:e99242.
54. Sporn MB, Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer. Nature Publishing Group; 2012;12:564-71.
55. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, et al. Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Research. 2011;71:5081-9.
56. Hayes JD, McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol. Cell. 2006;21:732-4.
57. Hayes JD, Dinkova-Kostova AT, McMahon M. Cross-talk between transcription factors AhR and Nrf2: lessons for cancer chemoprevention from dioxin. Toxicological Sciences. 2009;111:199-201.
58. Wang X-J, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008;29:1235-43.
59. Rushworth SA, Bowles KM, MacEwan DJ. High Basal Nuclear Levels of Nrf2 in Acute Myeloid Leukemia Reduces Sensitivity to Proteasome Inhibitors. Cancer Research. 2011;71:1999-2009.
60. Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang Q, Munson PJ, et al. Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma. Clinical Cancer Research. 2011;17:5101-12.
61. Sharma A, Tripathi M, Satyam A, Kumar L. Study of antioxidant levels in patients with multiple myeloma. Leuk Lymphoma. 2009;50:809-15.
62. Stellrecht CM, Gandhi V. Myeloma antioxidant status: the good, the bad and the reactive. Leuk Lymphoma. 2009;50:691-3.
63. Gangemi S, Allegra A, Alonci A, Cristani M, Russo S, Speciale A, et al. Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm. Res. 2012;61:1063-7.
64. Goel A, Spitz DR, Weiner GJ. Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma. J. Cell. Biochem. 2012;113:419-25.
65. Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol. 2008;141:494-503.
66. Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I, et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol. 2003;82:654-9.
67. De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, Pellet F, Pantesco V, Reme T, Jourdan M, Rossi JF, and Klein B. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene, 2002, 21, 6848-6857.
68. Barlogie B. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107:2633-8.
69. Yang L, Price ET, Chang C-W, Li Y, Huang Y, Guo L-W, et al. Gene Expression Variability in Human Hepatic Drug Metabolizing Enzymes and Transporters. Miao X-P, editor. PLoS ONE. 2013;8:e60368.